The New York State Department of Health’s Wadsworth Center said it is filling laboratory testing gaps triggered by the US Centers for Disease Control and Prevention’s pause on testing for multiple infectious diseases. The CDC action, described as following staff layoffs and resignations, risks delaying case detection and weakening surveillance and reporting. Wadsworth said it received more than 13,000 samples from 23 states in 2025 and will assist jurisdictions in New York and beyond while the CDC pause is in place. The development matters for biotech and med-tech stakeholders with diagnostics and surveillance-facing portfolios because it affects downstream test availability and local laboratory capacity. The immediate industry implication is increased variance in testing throughput and turnaround across regions, increasing the operational need for backup diagnostic capacity.